MedicQuant is developing a point-of-care diagnostic intended to rapidly quantify apixaban levels to inform acute stroke treatment decisions. The company aims to deliver clinically relevant results closer to the patient and faster than traditional laboratory workflows. MedicQuant’s development program includes clinical validation of the test to demonstrate precision, scalability, and usability in clinical settings. The company originates from Aarhus University and leverages over 11 years of DNA-nanotechnology research. Financially, MedicQuant completed a 22 million DKK seed round earlier this year led by Delphinus Venture Capital with EIFO as a follow-on investor, and has secured a €2.5 million EIC grant with potential for up to €4 million in equity from the EIC Fund to support its next stage of development.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026